Literature DB >> 15995967

Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.

Kamolwish Laoprasopwattana1, Daniel H Libraty, Timothy P Endy, Ananda Nisalak, Supamit Chunsuttiwat, David W Vaughn, George Reed, Francis A Ennis, Alan L Rothman, Sharone Green.   

Abstract

BACKGROUND: Dengue hemorrhagic fever, the most severe form of dengue illness, is associated with secondary dengue virus (DV) infection. Preexisting nonneutralizing antibodies to DV that enhance the infection of Fc gamma receptor-bearing cells have been implicated in DV pathogenesis.
METHODS: We conducted a prospective cohort study in Thai schoolchildren. Enhancing activity (EA) was measured as the percentage of DV-infected K562 cells, and viral titer (infected K562 cell supernatants) was measured in preillness plasma samples from children who subsequently had secondary DV2 or DV3 infection.
RESULTS: Plaque-reduction neutralizing titers to the child's own DV2 or DV3 isolate were detected in 23 of 32 and 8 of 27 of the preillness plasma samples, and EA was detected to a low-passage Thai DV2 or DV3 in 31 of 32 and 26 of 27, respectively, of the samples. EA in undiluted preillness plasma did not correlate with subsequent disease severity or peak viremia levels in either secondary DV2 or DV3 infections.
CONCLUSIONS: Preillness plasma enhances DV infection of K562 cells even in the presence of detectable neutralizing antibodies in LLC-MK2 cells. However, levels of preillness plasma EA of DV infection in K562 cells did not correlate with the clinical severity or viral burden of secondary DV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995967     DOI: 10.1086/431520

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

Review 1.  Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas.

Authors:  G William Letson; Pratap Singhasivanon; Eduardo Fernandez; Nihal Abeysinghe; Juan Jose Amador; Harold S Margolis; Robert Edelman
Journal:  Hum Vaccin       Date:  2010-10-01

Review 2.  Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis.

Authors:  Karen Clyde; Jennifer L Kyle; Eva Harris
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 3.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

4.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

5.  Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.

Authors:  Annette A Kraus; William Messer; Laura B Haymore; Aravinda M de Silva
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

Review 6.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

7.  Dengue virus induces mitochondrial elongation through impairment of Drp1-triggered mitochondrial fission.

Authors:  Vincent Barbier; Diane Lang; Sierra Valois; Alan L Rothman; Carey L Medin
Journal:  Virology       Date:  2016-11-04       Impact factor: 3.616

8.  Prospects for a dengue vaccine: progress and pitfalls.

Authors:  Sarah L George
Journal:  Mo Med       Date:  2014 Jul-Aug

Review 9.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

10.  Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections.

Authors:  Jesse J Waggoner; Leah C Katzelnick; Raquel Burger-Calderon; Julia Gallini; Renee H Moore; Guillermina Kuan; Angel Balmaseda; Benjamin A Pinsky; Eva Harris
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.